Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This meta-analysis of 17 Phase 3 RCTs reveals that BTK inhibitors, primarily ibrutinib, increase the risk of non-fatal ischemic cardiovascular events in patients with B-cell malignancies, highlighting important safety considerations.
Achieving a ≥50% reduction in LDL-C from baseline independently reduces recurrent cardiovascular events post-ischemic stroke, suggesting that combining relative and absolute LDL-C targets improves long-term outcomes.
This analysis reveals that waist circumference and waist-to-hip ratio improve cardiovascular risk classification beyond BMI, identifying individuals with hidden risk and refining prognostic assessments across multiple cardiovascular outcome
A race-free adaptation of the MESA risk score estimates 10-year coronary heart disease risk with comparable accuracy to the original, challenging the necessity of including race/ethnicity in cardiovascular risk prediction.
The VasCog-2-WSO criteria effectively detect MRI-defined vascular cognitive impairment in asymptomatic adults, correlating with increased cardiovascular risk and mortality, highlighting their utility for early diagnosis and community risk s
A study of 305 individuals with type 2 diabetes found that blood-based DNA methylation models predicted 5-year major adverse cardiovascular events with high accuracy, suggesting potential for improved risk stratification.
This analysis of the SOUL trial shows oral semaglutide reduces major cardiovascular events, with greater benefits linked to higher baseline HbA1c and larger HbA1c reductions, while BMI changes did not significantly affect outcomes.
This study introduces and validates a simplified machine learning-based equation for estimating LDL cholesterol, showing comparable accuracy to the original Martin-Hopkins method and improved ease of use.
This study compares the predictive value of non-HDL cholesterol and apolipoprotein B for atherosclerotic cardiovascular disease risk in individuals not on lipid-lowering medication.
This study reveals that specific gene mutations and cardiovascular risk factors significantly influence prognosis and thrombotic risk in triple-negative essential thrombocythemia, highlighting the importance of molecular profiling for perso
This study from two Spanish cohorts explores how moderate wine consumption within a Mediterranean diet impacts cardiovascular disease and mortality, suggesting modest benefits but advising cautious interpretation.
A cohort study demonstrates increased major cardiovascular event risk in first-degree relatives of individuals with high plasma lipoprotein(a), supporting cascade screening for targeted prevention.
This study reveals that 21% of asymptomatic patients with mild HCM develop major adverse cardiovascular events over 7 years, highlighting key predictors such as age, symptom progression, and cardiac remodeling markers that inform management
Obicetrapib significantly lowers lipoprotein(a), LDL cholesterol, and apolipoprotein B in high cardiovascular risk patients, offering a promising addition to lipid-lowering therapies, especially for patients with mild to moderate Lp(a) elev
This review synthesizes current evidence on the modified sleep apnea severity index (mSASI) as a composite metric integrating clinical and sleep study factors to predict cardiovascular risk in CPAP-intolerant OSA patients undergoing surgery
In a Phase 1b placebo-controlled trial, ruvonoflast markedly reduced hsCRP, IL-6, and fibrinogen over 28 days in adults with obesity, elevated hsCRP, and cardiometabolic risk, supporting further evaluation of oral NLRP3 inhibition in athero
Higher blood IL-6 levels were strongly linked to nine cardiovascular and mortality outcomes in nearly 60,000 adults, supporting IL-6 as an important inflammatory marker and potential prevention target.
The SABRE model estimates which people with type 2 diabetes may benefit most from SGLT2 inhibitors to prevent heart failure before it develops.
A pooled analysis of 59,396 participants found that higher serum IL-6 concentrations independently predicted nine cardiovascular and mortality outcomes, with consistent associations across key clinical subgroups.
This review analyzes evidence comparing Familial Hypercholesterolemia (FH) across ancestries, highlighting that while pathogenic variant prevalence is similar, African ancestry individuals face higher LDL-C burdens and significant risks fro